Fundraising FoxNaurex
Evanston, US · 5 known investors
Find your way into Naurex
Sign up to see every warm intro you have to Naurex
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Naurex team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Developed next-generation depression pharmaceuticals; acquired in 2015 for $560M upfront plus milestones.
Founders & leadership
Board
Investors · 5
How we know: Cota Capital's portfolio page · Not right? Tell us
How we know: Latterell Venture Partners's portfolio page · Not right? Tell us
How we know: Sofinnova Ventures's portfolio page · Not right? Tell us
How we know: funding news · Not right? Tell us
Reported raises · per SEC filings
Form D private placements$105M disclosed across 2 rounds · 2014
▶$80MraisedDec 2014 · 61 investors · PharmaceuticalsRule 506(b)
- Kenneth J. WidderDirector
- Terry P. GouldDirector
- Robert J. HombachDirector
- Mitchell S. BloomExecutive Officer
- Wilbur H. GantzDirector
- Norbert G. RiedelExecutive Officer, Director
- Ashish KhannaExecutive Officer
- Ronald M. BurchExecutive Officer
- Mohamed Amin KhanExecutive Officer
- Derek A. SmallDirector
- James SchulzExecutive Officer
- Ian R. FerrierDirector
- Joseph R. MoskalExecutive Officer
- Amount sold
- $80M
- First sale
- Nov 2014
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$25MraisedMay 2014 · 40 investors · BiotechnologyRule 506(b)
- Amin KhanExecutive Officer
- Robert J. HombachDirector
- Wilbur H. GantzDirector
- James SchulzExecutive Officer
- Kenneth J. WidderDirector
- Mitchell S. BloomExecutive Officer
- Joseph R. MoskalExecutive Officer
- Ronald M. BurchExecutive Officer
- Ian FerrierDirector
- Norbert RiedelExecutive Officer, Director
- Terry GouldDirector
- Ashish KhannaExecutive Officer
- Amount sold
- $25M
- First sale
- May 2014
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Non-dilutive funding · 1 SBIR/STTR award
Federal grants — no equity taken| Agency | Phase | Year | Amount |
|---|---|---|---|
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2015 | $197.6K |
Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.
Frequently asked questions
- What does Naurex do?
- Developed next-generation depression pharmaceuticals; acquired in 2015 for $560M upfront plus milestones.
- Who founded Naurex?
- Naurex was founded by Joseph R. Moskal.
- Who are Naurex's investors?
- Naurex's investors include Cota Capital, EcoR1 Capital, Latterell Venture Partners, Sofinnova Ventures, Adams Street Partners.
- How much funding has Naurex raised?
- Naurex has disclosed $105M raised across 2 rounds.
- Where is Naurex headquartered?
- Naurex is headquartered in Evanston, US.